Barclays PLC Has $36.87 Million Stock Position in Sanofi (NASDAQ:SNY)

Barclays PLC boosted its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 107.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 639,772 shares of the company's stock after purchasing an additional 331,445 shares during the quarter. Barclays PLC's holdings in Sanofi were worth $36,869,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Magnetar Financial LLC increased its stake in Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company's stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. Jennison Associates LLC raised its holdings in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock valued at $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company's stock worth $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Trading Down 0.4 %

Shares of SNY stock traded down $0.19 on Friday, reaching $46.80. The company had a trading volume of 3,464,494 shares, compared to its average volume of 2,066,254. The stock has a market cap of $118.77 billion, a PE ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58. The company has a 50-day moving average of $51.02 and a 200-day moving average of $52.07. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the firm posted $2.55 earnings per share. Sanofi's revenue was up 12.3% compared to the same quarter last year. On average, equities analysts forecast that Sanofi will post 4.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of analyst reports. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday. Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.